ReviewClinical science (London, England : 1979)2022
Chronic obstructive pulmonary disease and atherosclerosis: common mechanisms and novel therapeutics.
Review in Clinical science (London, England : 1979), 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 41 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
41 citing papers in PubMed, 3 syntheses or guidelines pooled it.
- A Systematic Review and Meta-Analysis on the Safety and Efficacy of Rosuvastatin as an Adjunctive Therapy in Acute Exacerbations of Chronic Obstructive Pulmonary Disease.International journal of chronic obstructive pulmonary disease · 2025Pooled it
- The Efficacy and Safety of Budesonide/Glycopyrronium/Formoterol in the Treatment of COPD in the Elderly.Contrast media & molecular imaging · 2022Pooled it
- The prevalence of metabolic syndrome in chronic obstructive pulmonary disease: A systematic review and meta-analysis.Chronic respiratory diseasePooled it
- ECG-based risk factors for adverse cardiopulmonary events and treatment outcomes in COPD.The European respiratory journal · 2025Trial
- Article
- Article
- Chemical and Mechanical Regulation of Leukocyte Migration.Cold Spring Harbor perspectives in biology · 2026Review
- Long-Term Outcomes After Percutaneous Coronary Intervention According to the High-Sensitivity C-Reactive Protein-to-Albumin Ratio in Patients With Chronic Obstructive Pulmonary Disease in China.Reviews in cardiovascular medicine · 2026Article
- Efficacy and safety of pharmacotherapy in COPD with arteriosclerosis: protocol for a systematic review and network meta-analysis.BMJ open · 2026Article
- Beyond the Usual Suspects: A Narrative Review of High-Yield Non-Traditional Risk Factors for Atherosclerosis.Journal of clinical medicine · 2026Review
- Development and validation of a nomogram prediction model for cardiovascular comorbidities in COPD patients based on hypertension.Frontiers in medicine · 2026Article
- Beyond the Lungs: A Narrative Review of Cardiopulmonary Risk Reduction and Management Perspectives in Thai COPD Patients.International journal of chronic obstructive pulmonary disease · 2026Review
- Article
- Cardiopulmonary risk in the COPD patient: the EPOCONSUL audit.Scientific reports · 2025Article
- Jianpi Yifei Tongluo recipe attenuates inflammation by promoting the expression of interferon regulatory factor 4 in the rat model of chronic obstructive pulmonary disease.Journal of traditional Chinese medicine = Chung i tsa chih ying wen pan · 2025Article
- Structure of Comorbidities and Causes of Death in Patients with Atrial Fibrillation and Chronic Obstructive Pulmonary Disease.Journal of clinical medicine · 2025Article
- (Pre-) atherosclerotic vessel changes in patients with chronic obstructive pulmonary disease and eosinophilia.BMC pulmonary medicine · 2025Article
- The sustained increase of cardiovascular risk following COPD exacerbations: meta-analyses of the EXACOS-CV studies.ERJ open research · 2025Article
- The Role of Inflammation in the Pathogenesis of Comorbidity of Chronic Obstructive Pulmonary Disease and Pulmonary Tuberculosis.International journal of molecular sciences · 2025Review
- Intelligent diagnosis and treatment model based on clinical data for home rehabilitation of chronic obstructive pulmonary disease.American journal of translational research · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Chronic obstructive pulmonary disease (COPD) and atherosclerosis are chronic irreversible diseases, that share a number of common causative factors including cigarette smoking. Atherosclerosis drastically impairs blood flow and oxygen availability to tissues, leading to life-threatening outcomes including myocardial infarction (MI) and stroke. Patients with COPD are most likely to die as a result of a cardiovascular event, with 30% of all COPD-related deaths being attributed to cardiovascular disease (CVD). Both atherosclerosis and COPD involve significant local (i.e. lung, vasculature) and systemic inflammation and oxidative stress, of which current pharmacological treatments have limited efficacy, hence the urgency for the development of novel life-saving therapeutics. Currently these diseases must be treated individually, with no therapies available that can effectively reduce the likelihood of comorbid CVD other than cessation of cigarette smoking. In this review, the important mechanisms that drive atherosclerosis and CVD in people with COPD are explained and we propose that modulation of both the oxidative stress and the inflammatory burden will provide a novel therapeutic strategy to treat both the pulmonary and systemic manifestations related to these diseases.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.